Alemtuzumab in the treatment of chronic lymphocytic leukemia.

Abstract

Alemtuzumab is a humanized therapeutic monoclonal antibody (MAb) that recognizes the CD52 antigen, expressed on normal and neoplastic lymphocytes, monocytes, and natural killer cells. In 2001, alemtuzumab was approved in the US and Europe to treat B-cell chronic lymphocytic leukemia (CLL) that had been treated previously with alkylating agents and was refractory to fludarabine. In heavily pretreated patients this MAb is able to produce response rates of about 40%, and in symptomatic, previously untreated patients response rates of more than 80% can be achieved. Alemtuzumab can also be used in patients with CLL as a preparative regimen for stem cell transplantation (SCT) and to prevent graft versus host disease. Moreover its in vivo use before or after SCT may also potentially result in depletion of residual leukemia cells, especially in the autologous setting. Adverse events associated with alemtuzumab include acute first-dose reaction, hematologic toxicity, and infectious complications. Usually they are predictable, manageable, and acceptable in the context of CLL. However, in a significant percentage of patients, cytomegalovirus reactivation occurs during alemtuzumab therapy, and routine weekly monitoring with the polymerase chain reaction methodology is indicated. Moreover, antiviral and antibacterial prophylaxis is mandatory.

• Authors: Tadeusz Robak
• Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (BioDrugs) Vol. 19 Issue 1 Pg. 9-22 ( 2005) ISSN: 1173-8804 [Print] New Zealand
• PMID: 15691213 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antibodies, Monoclonal, Murine-Derived
• Antibodies, Neoplasm
• Antigens, CD
• Antigens, Neoplasm
• Antineoplastic Agents
• CD52 Antigen
• CD52 protein, human
• Glycoproteins
• Alemtuzumab
• Rituximab

Topics

• Adult
• Aged
• Alemtuzumab
• Antibodies, Monoclonal (administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
• Antibodies, Monoclonal, Humanized
• Antibodies, Monoclonal, Murine-Derived
• Antibodies, Neoplasm (adverse effects, therapeutic use)
• Antigens, CD (immunology, metabolism)
• Antigens, Neoplasm (immunology, metabolism)
• Antineoplastic Agents (adverse effects, pharmacokinetics, therapeutic use)
• CD52 Antigen
• Clinical Trials as Topic
• Drug Administration Schedule
• Glycoproteins (immunology, metabolism)
• Half-Life
• Humans
• Infusions, Intravenous
• Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy)
• Middle Aged
• Rituximab
• Stem Cell Transplantation
• Treatment Outcome